What independent peptide purity testing actually involves.
A peptide purity figure comes from a specific analytical process, not a claim taken on trust: reversed-phase HPLC for purity, mass spectrometry for identity. Read through one real published AKH batch to see what that process produces, and what commissioning it independently involves and costs.
"Peptide purity testing" describes a specific pair of analytical methods, not a generic promise printed on a product page. Reversed-phase high-performance liquid chromatography (HPLC) separates a dissolved sample and measures how much of the detected material is one compound; mass spectrometry measures that compound's mass and checks it against the value the intended sequence predicts. Between them, the two methods answer two different questions — how pure, and is it even the right molecule — and a peptide testing report is only complete when both have been run.
This post is written for researchers and laboratory personnel who want to know what actually happens between a vial and a certificate: how HPLC and mass-spectrometry testing works, what independent testing involves when it is commissioned from outside a vendor, and what drives its cost. It walks through one certificate of analysis AKH BioLabs has published — a real batch, not a specimen — to show what the process produces on an actual report.
Key takeaways
- HPLC purity testing separates a dissolved sample on a column and measures the target compound's peak area as a percentage of everything detected — a measure of chromatographic purity, not a count of molecules or a mass balance.
- Mass spectrometry testing is a separate step: it measures the mass-to-charge ratio of the ionised sample and compares it with the mass the intended sequence predicts, which is what confirms identity rather than purity.
- A peer-reviewed peptide quality-control methodology paper describes exactly this pairing as standard practice — reversed-phase HPLC-UV for the chromatographic run, a mass-spectrometry detector on the same instrument for identifying the peptide and its impurities and evaluating peak purity.
- A real AKH batch — MOTS-C, batch 26158, tested by the Brown Institute of Biomolecular Research on 2026-08-06 — reports "MOTS-C: 40mg | Purity: 99.79%", the output of exactly this HPLC-plus-identity process on one named sample.
- Independent testing cost is driven by which analyses are commissioned, not by a single flat fee: an HPLC-purity-plus-identity pair is the baseline pairing described above, while endotoxin, heavy-metal or residual-water testing are separate, specifically ordered analyses on top of it.
The two-step process behind a purity figure
HPLC testing works by dissolving the sample and pumping it through a column packed with material that interacts differently with each component, so that different molecules travel through at different speeds and exit — elute — at different times. A detector, typically measuring ultraviolet absorbance for peptides, records each component as a peak on a trace as it elutes. Purity is then calculated by area normalisation: the target peak's area divided by the total area of every peak the run detected, expressed as a percentage.
Mass spectrometry testing works differently and answers a different question. The sample is ionised, and the resulting ions are separated and measured by their mass-to-charge ratio. For a peptide, the observed mass is compared against the theoretical mass calculated from its amino-acid sequence; a match within the instrument's stated tolerance is consistent with the intended molecule, and a substantially different mass is not — however clean the HPLC trace looked.
Neither method alone produces a complete testing result. A peer-reviewed quality-control methodology paper on peptide analysis states the point directly: during research use, "it is recommended to evaluate the test compound identity and purity in order to obtain reliable study outcomes," and describes standard practice as reversed-phase liquid chromatography on a C18 column coupled to a UV detector for the chromatographic run, with "a single quad mass spectrometry (MS) detector system during QC analysis of (cationic) peptides, allowing identification of the peptide and its impurities, as well as the evaluation of the peak purity." HPLC and mass spectrometry are not alternative ways of doing the same test — they are the two halves of one testing process, purity from one and identity from the other.
Reading one actual AKH batch
The process is easiest to see against a genuine report rather than a description of one. This is a real batch AKH BioLabs has published, not a specimen: MOTS-C, batch 26158, tested by the Brown Institute of Biomolecular Research on 2026-08-06. Every field below is taken from that report.
| Field | Value on this batch |
|---|---|
| Product | MOTS-C |
| Batch | 26158 |
| Test date | 2026-08-06 |
| Laboratory | Brown Institute of Biomolecular Research |
| Report reference | #1812454 |
| Result | MOTS-C: 40mg | Purity: 99.79% |
"40mg" is the labelled fill mass
A quantity claim about the vial's contents, measured and stated independently of the purity figure on the same line.
"99.79%" is the HPLC purity figure
The target peak's share of everything the chromatography run detected on this batch, on this test date, in this laboratory — the output of the HPLC half of the testing process described above.
A named batch and a named laboratory
Batch 26158 and the Brown Institute of Biomolecular Research are both stated on the report, which is what makes the result checkable against a specific run rather than a general claim.
The report reference is a lookup key
#1812454 is the laboratory's own reference for this analysis — the identifier a reader can use to connect the published figure back to the laboratory's record.
Why independent testing is the meaningful qualifier
"Independent" testing means the laboratory performing the analysis is not the vendor selling the material — a separate party with no stake in the result. That distinction matters because the online market for research compounds is, by design, unregulated in the way a pharmaceutical supply chain is not: no agency inspects every batch before it reaches a buyer, and a vendor's own unverified claim about a product's contents is, on its own, exactly that — a claim.
The scale of that risk has been measured directly, if not for peptides specifically. A 2017 analysis published in JAMA examined 44 products marketed and sold via the internet as selective androgen receptor modulators — a similarly unregulated online market for research compounds — using chain-of-custody analytical testing. Only 52% of the products contained a selective androgen receptor modulator at all; substances not listed on the label were found in 25% of products, and the amount of labelled compound differed substantially from the amount actually present in 59% of products tested. The study is not about peptides, and this post does not claim otherwise — it is evidence about the class of market a peptide buyer is also operating in: one where the label and the vial are two separate claims until an independent laboratory has connected them.
AKH BioLabs' own published certificates already show what a multi-laboratory testing arrangement looks like in practice: certificates published on this site name the Brown Institute of Biomolecular Research for the great majority of batches, and Janoshik Analytical for at least one product's report, both named independent laboratories rather than an in-house or unstated tester.
What commissioning independent testing involves
Independent peptide testing, commissioned outside a vendor, follows the same two-step process described above, run by a laboratory with no commercial interest in the outcome. A sample is sent to the laboratory, which runs it through its own HPLC and mass-spectrometry instruments against its own reference standards and returns a report naming the batch tested, the method used, the date, and the numerical results — the same elements a published certificate of analysis carries.
What is commissioned, not a single flat service, is what drives testing cost. The HPLC-purity-plus-mass-spectrometry-identity pairing described above is the baseline analysis; it is what answers whether the vial contains the intended compound and how chromatographically pure it is. Additional, separately commissioned analyses — endotoxin testing, heavy-metal screening, Karl Fischer water content, or net peptide content by amino-acid analysis — extend that baseline and add to its cost, because each is a distinct method run on the same or an additional sample. A laboratory's turnaround time and whether a sample is tested once or in replicate are further, non-trivial cost variables. None of this reduces to one number that applies across laboratories or compounds, which is why a specific cost figure is not asserted here: any given quote is a laboratory's own answer to what, exactly, is being commissioned.
- 01
Confirm the laboratory is genuinely independent
Named, third-party, and not the vendor selling the material under test.
- 02
Specify HPLC purity and mass-spectrometric identity as the baseline
Both, not one — a purity figure with no identity check leaves open the possibility of a clean trace of the wrong molecule.
- 03
Add only the analyses actually needed
Endotoxin, heavy metals, water content and net peptide content are separate, specifically ordered tests, each adding to scope and cost beyond the HPLC-plus-identity baseline.
- 04
Expect a report naming the batch, method, date and laboratory
Anything less is not a testing result that can be checked against its source.
What HPLC and mass spectrometry testing does not cover
The two-method process described here answers chemical questions about identity and purity. It does not test for microbial contamination or bacterial endotoxin — both require a separate, specifically commissioned assay — and it says nothing about a compound's biological activity or effect. A testing report is a statement about one sample from one batch on one test date; it is not a statement about a different vial, a later date, or anything the compound does once it leaves the laboratory.
Common questions.
- How does HPLC testing work for peptides?
A dissolved sample is pumped through a chromatography column that separates its components by how they interact with the column material, and a detector — usually ultraviolet, for peptides — records each component as it elutes. Purity is calculated by area normalisation: the target compound's peak area divided by the total area of every peak the run detected, expressed as a percentage. It is a chromatographic measurement, not a count of molecules or a statement of mass.
- What does independent peptide testing involve?
A sample is sent to a named third-party laboratory with no commercial stake in the vendor's sales, which runs it through its own HPLC and mass-spectrometry instruments against its own reference standards. The laboratory returns a report naming the batch, the method, the test date and the numerical results — the same elements a published certificate of analysis is expected to carry, produced by a party independent of the seller.
- How much does independent peptide testing cost?
There is no single figure, because cost follows scope. An HPLC-purity-plus-mass-spectrometry-identity pairing is the baseline analysis; endotoxin testing, heavy-metal screening, water content and net peptide content are separate, specifically commissioned analyses added on top of that baseline, and turnaround time and replicate testing add further variation. A quoted cost from any laboratory is an answer to what was actually commissioned, not a fixed industry price.
- Can HPLC testing alone confirm a peptide's identity?
No. HPLC measures how much of the detected material is one compound relative to everything else the run detected; it does not by itself establish which compound that is. Identity confirmation is a separate step, performed by mass spectrometry, which measures the sample's mass and compares it against the value the intended sequence predicts. A clean HPLC trace with no identity check has not confirmed what the peak actually is.
Sources
- 01Stalmans S, Gevaert B, Verbeke F, D'Hondt M, Bracke N, Wynendaele E, De Spiegeleer B. "Quality control of cationic cell-penetrating peptides." J Pharm Biomed Anal. 2016 Jan 5;117:289-97.
- 02Van Wagoner RM, Eichner A, Bhasin S, Deuster PA, Eichner D. "Chemical Composition and Labeling of Substances Marketed as Selective Androgen Receptor Modulators and Sold via the Internet." JAMA. 2017 Nov 28;318(20):2004-2010.
- 03AKH BioLabs certificate of analysis — MOTS-C, batch 26158, Brown Institute of Biomolecular Research, 2026-08-06